<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "https://jats.nlm.nih.gov/publishing/1.3/JATS-journalpublishing1-3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">ijgah</journal-id>
      <journal-title-group>
        <journal-title>International Journal of Gastroenterology and Hepatology</journal-title>
      </journal-title-group>
      <issn publication-format="electronic">2834-0884</issn>
      <publisher>
        <publisher-name>International Journal of Gastroenterology and Hepatology</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories>
      <title-group>
        <article-title>Benefits of Biosimilars in Inflammatory Bowel Disease, Issues, and Future Directions</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Feagan</surname>
            <given-names>Brian</given-names>
          </name>
          <aff>Onuigbo, Department of Pathology, Medical Foundation and Clinic, Enugu, Nigeria.</aff>
        </contrib>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>01</day>
        <month>01</month>
        <year>2022</year>
      </pub-date>
      <permissions>
        <copyright-statement>© 2022 The Author(s). Published by International Journal of Gastroenterology and Hepatology.</copyright-statement>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>BF The primary advantage of utilizing biosimilars in patients with fiery entrail sickness (IBD) is diminished medication obtaining costs. Biosimilars are not conventional medications — they are profoundly like originator biologic specialists — in any case, similar to generics, biosimilars are more affordable than the originators. In many nations, biologic medications have turned into a weight on drug store spending plans. In IBD explicitly, biologic specialists are presently the quickest developing spending plan things. This present circumstance is a significant worry for both drug store benefits chiefs and patients, who are progressively taking care of a piece of medication costs...</p>
      </abstract>
    </article-meta>
  </front>
</article>
